Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Tellgen

Tellgen?uq=BoBgMMEs
2003 FOUNDED
PUBLIC STATUS
301-400 EMPLOYEES
300642 STOCK SYMBOL
$6.57 SHARE PRICE (As of Wednesday Closing)
Description

Developer of vitro diagnostic reagents intended to treat tumor, infectious and reproductive diseases. The company is focused in development and manufacturing of tumor markers screening and gene mutation detection technology for clinical diagnosis, research use and health centers.

Website
Formerly Known As
Through King Life Technology
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Stock Exchange
SHE
Primary Office
  • Building 1, No.115, Lane 572
  • Bibo Road, Free Trade Zone
  • Shanghai, Pudong 201203
  • China

+86 021 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tellgen’s full profile, request a free trial.

Tellgen Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$5.24 - $11.69 $596M $6.56 $0.24 1.16M 90.8M

Tellgen Financials Summary

In Thousands,
USD
TTM
30-Sep-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 518,557 767,571
Revenue 53,301 44,820 34,713 26,973
EBITDA 27,722 24,330 19,652 14,324
Net Income 21,479 18,765 14,678 10,475
Total Assets 153,465 143,239 49,041 35,552
Total Debt 0 0 2,214 1,725
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tellgen Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Tellgen‘s full profile, request access.

Request full access to PitchBook

Tellgen Executive Team (1)

Name Title Board
Seat
Contact
Info
Jianer Yao Chief Executive Officer